JPMorgan analyst Hardik Parikh initiated coverage on Viking Therapeutics Inc VKTX with an Overweight rating and a December 2025 price target of $80, which implies a potential 45% upside from its current price of $54.65. At the core of this bullish outlook is Viking's obesity drug candidate, oral-2735, which could be a significant player in the rapidly expanding GLP-1 market. Oral-2735 Could Be A Game Changer JPMorgan highlights oral-2735's potential as a highly competitive treatment in the GLP-1 market, par ...

The latest trading session saw Viking Therapeutics, Inc. (VKTX) ending at $54.78, denoting a +1.2% adjustment from its last day's close. This move outpaced the S&P 500's daily gain of 1.16%. Elsewhere, the Dow gained 1.2%, while the tech-heavy Nasdaq added 1.16%. The company's stock has dropped by 5.3% in the past month, falling short of the Medical sector's gain of 4.5% and the S&P 500's gain of 3.48%. The upcoming earnings release of Viking Therapeutics, Inc. will be of great interest to investors. The co ...

The huge demand for effective new weight management drugs has billionaire investors feeling bullish about this stock. Wall Street investment banks keep pounding the table on Viking Therapeutics (VKTX -2.27%) and its weight loss drug candidate. Predictions vary, but the average analyst who follows the stock thinks it can rise 98% from recent prices. Investment bank analysts aren't the only folks on Wall Street who think the clinical-stage biopharma has a bright future. In the second quarter, billionaire mone ...

Viking Therapeutics, Inc. (VKTX) closed the most recent trading day at $58.10, moving -0.5% from the previous trading session. The stock trailed the S&P 500, which registered a daily loss of 0.16%. Meanwhile, the Dow gained 0.09%, and the Nasdaq, a tech-heavy index, lost 0.3%. Coming into today, shares of the company had gained 9.49% in the past month. In that same time, the Medical sector gained 4.7%, while the S&P 500 gained 3.64%. The investment community will be paying close attention to the earnings pe ...

Shares of Viking Therapeutics (VKTX) have more than tripled in market value in the past year. The upside was triggered by positive updates on its pipeline programs for obesity and non-alcoholic steatohepatitis (NASH) indications. Based on the encouraging results, management intends to meet with the FDA to discuss the late-stage study design and timings for both programs. In the past year, the stock has significantly outperformed the industry's 2.5% decline. The stock has outperformed the sector and the S&P ...

The recommendations of Wall Street analysts are often relied on by investors when deciding whether to buy, sell, or hold a stock. Media reports about these brokerage-firm-employed (or sell-side) analysts changing their ratings often affect a stock's price. Do they really matter, though? Before we discuss the reliability of brokerage recommendations and how to use them to your advantage, let's see what these Wall Street heavyweights think about Viking Therapeutics, Inc. (VKTX) . Viking Therapeutics currently ...

The new drugs this company is developing could be worth a lot more than the present market value of its stock. Shares of Viking Therapeutics (VKTX 0.43%), a clinical-stage drugmaker working on metabolic treatments, have tripled in value this year. Despite the huge run-up, analysts who follow the company think it has heaps more upside. The average analyst who follows Viking Therapeutics thinks it can rise to $113.55 per share. Reaching the consensus expectation would result in a gain of about 76% from the st ...

Shares of Viking Therapeutics (VKTX) have soared nearly 25% in the past month, all thanks to progress with its investigational obesity and non-alcoholic steatohepatitis (NASH) candidates, which management plans to advance to late-stage development by early 2025. Last month, alongside its second-quarter earnings results, VKTX reported that it had received feedback from the FDA regarding the next steps in the developmental pathway for the obesity drug VK2735. Based on such feedback, the company is gearing up ...

One preliminary piece of evidence is sending its shares higher. Viking Therapeutics (VKTX 2.01%) just gave shareholders a few more reasons to be excited for the future. With its shares soaring by a stunning 34% on July 25 thanks to second-quarter earnings, the bull thesis for its continued outperformance is stronger than ever. It's clear now that the biotech has what it'll need to take on powerful competitors like Eli Lilly and Novo Nordisk. Here's why. Strong clinical data and minimal expenditures make a v ...

All of this has pushed shares of Viking to major gains this year, with performance even surpassing that of AI powerhouse Nvidia. Viking is developing injectable and oral GIP and GLP-1 receptor agonists, treatments that act on hormones controlling blood sugar levels and appetite. Just last week, the company said it's advancing VK-2735, its injectable candidate, into a phase 3 trial and has scheduled an end-of-phase 2 meeting with the U.S. Food and Drug Administration for later this year. In the phase 2 trial ...